Free Trial
→ Watch This Robotics Demo Before July 23rd (From Brownstone Research) (Ad) Buy ATXS Stock  Free ATXS Stock Alerts

Astria Therapeutics (ATXS) Financials

Astria Therapeutics logo
$3.92 -0.16 (-3.92%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$3.92 0.00 (0.00%)
As of 05/23/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Astria Therapeutics

Annual Income Statements for Astria Therapeutics

This table shows Astria Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders		 -94 -73 -52
Consolidated Net Income / (Loss)		 -94 -73 -52
Net Income / (Loss) Continuing Operations		 -94 -73 -52
Total Pre-Tax Income 		-94 -73 -52
Total Operating Income		 -112 -83 -54
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 112 83 54
Selling, General & Admin Expense		 34 26 19
Research & Development Expense		 77 57 34
Total Other Income / (Expense), net		 17 10 1.67
Interest & Investment Income		 17 10 1.72
Other Income / (Expense), net		 -0.06 -0.06 -0.06
Basic Earnings per Share		 ($1.68) ($2.42) ($3.55)
Weighted Average Basic Shares Outstanding		 56.16M 30.12M 14.62M
Diluted Earnings per Share		 ($1.68) ($2.42) ($3.55)
Weighted Average Diluted Shares Outstanding		 56.16M 30.12M 14.62M
Weighted Average Basic & Diluted Shares Outstanding		 56.43M 54.90M 27.99M

Quarterly Income Statements for Astria Therapeutics

This table shows Astria Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -26 -25 -24 -20 -31 -18 -13 -11 - -12
Consolidated Net Income / (Loss)		 -26 -25 -24 -20 -31 -18 -13 -11 - -12
Net Income / (Loss) Continuing Operations		 -26 -25 -24 -20 -31 -18 -13 -11 - -12
Total Pre-Tax Income 		-26 -25 -24 -20 -31 -18 -13 -11 - -12
Total Operating Income		 -30 -29 -29 -24 -34 -20 -15 -13 - -12
Total Operating Expenses		 30 29 29 24 34 20 15 13 - 12
Selling, General & Admin Expense		 9.43 8.50 8.09 8.42 7.33 6.90 6.01 5.46 - 4.69
Research & Development Expense		 20 21 21 16 27 13 9.09 8.03 - 7.70
Total Other Income / (Expense), net		 3.97 4.48 4.63 4.22 2.79 2.51 2.54 2.31 - 0.39
Interest & Investment Income		 3.96 4.52 4.65 4.24 2.80 2.53 2.56 2.32 - 0.44
Other Income / (Expense), net		 0.01 -0.04 -0.02 -0.02 -0.01 -0.02 -0.02 -0.02 - -0.05
Basic Earnings per Share		 ($0.45) ($0.42) ($0.43) ($0.38) ($0.94) ($0.63) ($0.45) ($0.40) - ($0.87)
Weighted Average Basic Shares Outstanding		 56.16M 57.82M 56.49M 52.29M 30.12M 28.04M 28.02M 27.94M 14.62M 13.74M
Diluted Earnings per Share		 ($0.45) ($0.42) ($0.43) ($0.38) ($0.94) ($0.63) ($0.45) ($0.40) - ($0.87)
Weighted Average Diluted Shares Outstanding		 56.16M 57.82M 56.49M 52.29M 30.12M 28.04M 28.02M 27.94M 14.62M 13.74M
Weighted Average Basic & Diluted Shares Outstanding		 56.43M 56.43M 112.85M 54.91M 54.90M 36.30M - 28.03M 27.99M 16.83M

Annual Cash Flow Statements for Astria Therapeutics

This table details how cash moves in and out of Astria Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents		 -116 155 -66
Net Cash From Operating Activities		 -81 -68 -44
Net Cash From Continuing Operating Activities		 -81 -68 -44
Net Income / (Loss) Continuing Operations		 -94 -73 -52
Consolidated Net Income / (Loss)		 -94 -73 -52
Amortization Expense		 -5.61 -0.09 -
Non-Cash Adjustments To Reconcile Net Income		 13 6.34 6.23
Changes in Operating Assets and Liabilities, net		 5.27 -1.80 2.07
Net Cash From Investing Activities		 -192 135 -167
Net Cash From Continuing Investing Activities		 -192 135 -167
Purchase of Property, Plant & Equipment		 -0.33 -0.03 -0.09
Purchase of Investments		 -4,245 -1,924 -396
Sale and/or Maturity of Investments		 4,053 2,060 229
Net Cash From Financing Activities		 157 88 145
Net Cash From Continuing Financing Activities		 157 88 145
Issuance of Debt		 35 28 -
Issuance of Common Equity		 117 59 145
Other Financing Activities, net		 4.79 0.42 0.08

Quarterly Cash Flow Statements for Astria Therapeutics

This table details how cash moves in and out of Astria Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -21 -6.48 -85 -3.52 56 -14 -68 182 -25 16
Net Cash From Operating Activities		 -17 -28 -17 -19 -30 -14 -11 -13 -11 -10
Net Cash From Continuing Operating Activities		 -17 -28 -17 -19 -30 -14 -11 -13 -11 -10
Net Income / (Loss) Continuing Operations		 -26 -25 -24 -20 -31 -18 -13 -11 -13 -12
Consolidated Net Income / (Loss)		 -26 -25 -24 -20 -31 -18 -13 -11 -13 -12
Amortization Expense		 -1.38 -1.73 - - - - - - - -
Non-Cash Adjustments To Reconcile Net Income		 3.41 3.63 4.26 2.08 2.07 1.70 1.37 1.19 1.05 1.26
Changes in Operating Assets and Liabilities, net		 6.23 -5.33 5.63 -1.25 -0.90 1.77 0.58 -3.26 1.55 0.49
Net Cash From Investing Activities		 -3.72 6.19 -68 -126 -2.02 -0.00 -58 195 -135 1.95
Net Cash From Continuing Investing Activities		 -3.72 6.19 -68 -126 -2.02 -0.00 -58 195 -135 1.95
Purchase of Investments		 -749 -1,059 -1,388 -1,049 -708 -914 -207 -96 -179 -53
Sale and/or Maturity of Investments		 745 1,065 1,320 923 706 914 149 291 43 55

Annual Balance Sheets for Astria Therapeutics

This table presents Astria Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets		 342 255 231
Total Current Assets		 335 251 228
Cash & Equivalents		 60 176 21
Short-Term Investments		 268 71 206
Prepaid Expenses		 6.51 4.41 1.25
Plant, Property, & Equipment, net		 0.00 0.00 0.00
Total Noncurrent Assets		 7.72 3.72 2.94
Other Noncurrent Operating Assets		 7.72 3.72 2.94
Total Liabilities & Shareholders' Equity		 342 255 231
Total Liabilities		 23 12 9.42
Total Current Liabilities		 19 12 9.06
Accounts Payable		 4.32 1.51 0.79
Accrued Expenses		 13 9.71 7.69
Other Current Liabilities		 1.38 0.33 0.58
Total Noncurrent Liabilities		 3.97 0.00 0.36
Other Noncurrent Operating Liabilities		 3.97 0.00 0.36
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 319 243 221
Total Preferred & Common Equity		 319 243 221
Preferred Stock		 95 95 96
Total Common Equity		 224 148 125
Common Stock		 899 728 633
Retained Earnings		 -675 -581 -508
Accumulated Other Comprehensive Income / (Loss)		 0.16 0.00 -0.08

Quarterly Balance Sheets for Astria Therapeutics

This table presents Astria Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 362 368 379 194 207 218 120
Total Current Assets		 352 358 375 191 204 215 118
Cash & Equivalents		 81 87 172 120 134 202 46
Short-Term Investments		 263 267 198 69 69 11 71
Prepaid Expenses		 7.58 3.19 4.61 2.66 1.46 2.12 1.91
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 9.78 10 4.29 2.40 2.64 2.80 1.33
Other Noncurrent Operating Assets		 9.78 10 4.29 2.40 2.64 2.80 1.33
Total Liabilities & Shareholders' Equity		 362 368 379 194 207 218 120
Total Liabilities		 20 21 11 9.38 6.65 6.88 6.95
Total Current Liabilities		 16 16 11 9.38 6.60 6.67 6.44
Accounts Payable		 1.28 2.34 0.86 1.14 0.83 0.93 0.79
Accrued Expenses		 13 13 10 7.76 5.18 5.16 5.07
Other Current Liabilities		 1.38 1.25 0.17 0.49 0.59 0.59 0.58
Total Noncurrent Liabilities		 4.26 4.54 0.00 0.00 0.05 0.21 0.50
Other Noncurrent Operating Liabilities		 4.26 4.54 - 0.00 0.05 0.21 0.50
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 342 347 368 184 200 211 113
Total Preferred & Common Equity		 342 347 368 184 200 211 113
Preferred Stock		 95 95 95 95 95 95 96
Total Common Equity		 246 252 272 89 105 116 16
Common Stock		 895 876 873 638 636 635 511
Retained Earnings		 -649 -625 -600 -549 -531 -519 -494
Accumulated Other Comprehensive Income / (Loss)		 0.33 -0.05 -0.01 0.00 0.00 -0.00 -0.22

Annual Metrics And Ratios for Astria Therapeutics

This table displays calculated financial ratios and metrics derived from Astria Therapeutics' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 -40.94% -55.30% 72.54%
EBIT Growth		 -34.33% -55.14% 72.54%
NOPAT Growth		 -34.36% -55.19% 72.56%
Net Income Growth		 -29.32% -40.62% 73.41%
EPS Growth		 30.58% 31.83% 85.56%
Operating Cash Flow Growth		 -18.65% -57.23% -44.38%
Free Cash Flow Firm Growth		 -21.20% -69.15% 74.24%
Invested Capital Growth		 -159.78% 34.61% -63.31%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -0.85% -31.78% 0.00%
EBIT Q/Q Growth		 3.98% -31.64% 0.00%
NOPAT Q/Q Growth		 3.97% -31.54% 0.00%
Net Income Q/Q Growth		 5.78% -33.15% 0.00%
EPS Q/Q Growth		 22.58% -24.10% 0.00%
Operating Cash Flow Q/Q Growth		 13.69% -40.05% -11.18%
Free Cash Flow Firm Q/Q Growth		 12.50% -37.59% 0.00%
Invested Capital Q/Q Growth		 -237.35% 21.10% 0.00%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 200.00% 100.00%
Interest Burden Percent		 84.45% 175.45% 96.78%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -33.52% -31.40% -30.18%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -22.16% -18.43% -13.24%
Return on Equity Simple (ROE_SIMPLE)		 -29.52% -29.98% 0.00%
Net Operating Profit after Tax (NOPAT)		 -78 -58 -37
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.63% -6.25% -8.17%
Return On Investment Capital (ROIC_SIMPLE)		 -24.46% -23.91% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -112 -83 -54
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -117 -83 -54
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 2.24 1.57 1.74
Price to Tangible Book Value (P/TBV)		 2.24 1.57 1.74
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.02 -1.02
Leverage Ratio		 1.06 2.09 1.04
Compound Leverage Factor		 0.90 1.83 1.01
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 29.86% 78.42% 43.58%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 70.14% 60.79% 56.42%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 10.31 17.76 11.16
Noncontrolling Interest Sharing Ratio		 33.90% 41.29% 56.12%
Liquidity Ratios		 - - -
Current Ratio		 17.49 21.73 25.13
Quick Ratio		 17.15 21.34 24.99
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -73 -60 -35
Operating Cash Flow to CapEx		 -24,988.31% -273,780.00% -47,838.46%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -8.87 -3.41 -5.22
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -5.46 1.81 -2.02
Enterprise Value (EV)		 269 80 88
Market Capitalization		 502 231 218
Book Value per Share		 $3.97 $4.07 $7.42
Tangible Book Value per Share		 $3.97 $4.07 $7.42
Total Capital		 319 243 221
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -328 -247 -226
Capital Expenditures (CapEx)		 0.33 0.03 0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -13 -7.14 -7.81
Debt-free Net Working Capital (DFNWC)		 316 239 219
Net Working Capital (NWC)		 316 239 219
Net Nonoperating Expense (NNE)		 16 15 14
Net Nonoperating Obligations (NNO)		 -328 -247 -226
Total Depreciation and Amortization (D&A)		 -5.61 -0.09 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($1.68) ($2.42) ($3.55)
Adjusted Weighted Average Basic Shares Outstanding		 56.16M 30.12M 14.62M
Adjusted Diluted Earnings per Share		 ($1.68) ($2.42) ($3.55)
Adjusted Weighted Average Diluted Shares Outstanding		 56.16M 30.12M 14.62M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 56.43M 54.90M 27.99M
Normalized Net Operating Profit after Tax (NOPAT)		 -78 -58 -37
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Astria Therapeutics

This table displays calculated financial ratios and metrics derived from Astria Therapeutics' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 9.49% -51.95% -90.58% -157.82% 0.00% -125.78% 0.00% 12.15% 100.00% -57.27%
EBIT Growth		 13.52% -43.43% -90.58% -157.82% 0.00% -62.89% 0.00% 12.15% 100.00% -57.27%
NOPAT Growth		 13.47% -43.38% -90.72% -157.96% 0.00% -126.76% 0.00% 12.26% 100.00% -56.82%
Net Income Growth		 18.41% -38.40% -92.36% -156.24% 0.00% -47.76% 0.00% 26.99% 0.00% -52.42%
EPS Growth		 52.13% 33.33% 4.44% 10.00% 0.00% 27.59% 0.00% 66.10% 0.00% -42.62%
Operating Cash Flow Growth		 42.58% -96.14% -56.98% -88.15% 0.00% -39.12% 0.00% -5.53% 0.00% -32.26%
Free Cash Flow Firm Growth		 40.73% -62.57% 0.00% -57.45% -1,372.05% -114.22% 0.00% 28.42% 126.22% 18.20%
Invested Capital Growth		 -159.78% 39.24% -198.36% -10.37% 34.61% -33.96% 0.00% 37.12% -63.31% -174.41%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -0.60% -6.79% -19.24% 29.34% -68.89% -33.94% -23.88% 0.00% 100.00% -8.46%
EBIT Q/Q Growth		 -1.82% -0.81% -19.24% 58.69% -137.78% -33.94% -23.88% 0.00% 100.00% -8.46%
NOPAT Q/Q Growth		 -1.99% -0.73% -19.27% 29.38% -69.00% -67.99% -23.85% 0.00% 100.00% -8.18%
Net Income Q/Q Growth		 -4.45% -1.50% -42.59% 36.56% -154.37% -41.07% -12.32% 0.00% 0.00% -6.64%
EPS Q/Q Growth		 -7.14% 2.33% -26.32% 59.57% -49.21% -80.00% -25.00% 0.00% 0.00% -1.16%
Operating Cash Flow Q/Q Growth		 37.92% -66.55% 12.06% 73.71% -224.15% -33.30% 38.59% 0.00% 0.00% -1.87%
Free Cash Flow Firm Q/Q Growth		 30.67% -45.82% 19.27% 0.00% -90.19% 0.00% 200.00% 0.00% 132.03% 16.59%
Invested Capital Q/Q Growth		 -237.35% 65.53% -502.21% 36.38% 42.20% -69.29% -59.76% 0.00% -41.15% -20.92%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 200.00% 100.00% 100.00% 200.00% 100.00% 0.00% 100.00%
Interest Burden Percent		 86.63% 84.45% 167.75% 82.45% 183.65% 87.52% 166.20% 82.82% 0.00% 96.49%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -33.52% -38.03% -34.06% -56.39% -31.40% -36.82% 0.00% 0.00% -30.18% -39.51%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -22.16% -24.25% -22.20% -37.82% -36.87% -13.08% 0.00% 0.00% -13.24% -8.20%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -29.28% -26.86% -44.40% 0.00% -29.68% 0.00% 0.00% 0.00% -42.58%
Net Operating Profit after Tax (NOPAT)		 -21 -20 -20 -17 -24 -14 -11 -9.45 0.00 -8.67
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.71% -1.58% -1.44% -2.07% -6.19% -2.33% -1.97% -1.07% 0.00% -2.68%
Return On Investment Capital (ROIC_SIMPLE)		 -6.49% - - - -9.85% - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -30 -29 -29 -24 -34 -20 -15 -14 0.00 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -31 -31 -29 -24 -34 -20 -15 -14 0.00 -12
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.24 2.58 2.04 5.40 1.57 2.35 2.22 3.20 1.74 7.54
Price to Tangible Book Value (P/TBV)		 2.24 2.58 2.04 5.40 1.57 2.35 2.22 3.20 1.74 7.54
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.01 -1.02 -1.01 -1.02 -1.03 -2.03 -1.02 -1.02 -1.02
Leverage Ratio		 1.06 1.06 2.10 2.06 1.05 1.05 1.04 1.04 1.04 1.05
Compound Leverage Factor		 0.92 0.89 0.88 1.70 1.92 1.85 0.87 0.86 0.00 1.01
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 29.86% 27.90% 54.93% 51.84% 39.21% 103.34% 95.13% 45.10% 43.58% 85.40%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 70.14% 72.10% 145.07% 148.16% 121.58% 96.66% 104.87% 54.90% 56.42% 14.60%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 11.10 17.45 13.23 77.22 19.02 10.19 18.37 30.03 11.93 5.74
Noncontrolling Interest Sharing Ratio		 33.90% 36.24% 34.82% 65.84% 41.29% 128.95% 127.89% 59.72% 56.12% 79.24%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 17.49 22.38 21.87 67.65 43.45 40.82 30.98 32.29 25.13 18.40
Quick Ratio		 17.15 21.90 43.34 33.41 42.69 20.12 61.52 31.97 24.99 18.10
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -15 -22 -15 -17 -26 -14 0.00 -11 2.02 -6.32
Operating Cash Flow to CapEx		 0.00% -139,825.00% -5,505.25% 0.00% -377,975.00% -712,900.00% 0.00% -265,060.00% 0.00% -17,670.69%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -8.87 -2.63 -7.63 -2.17 -3.41 -4.33 -2.56 -1.97 -5.22 -3.70
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -5.46 1.70 -5.07 -0.20 1.81 -0.63 0.00 1.16 -2.02 -2.35
Enterprise Value (EV)		 269 388 255 461 80 116 126 254 88 104
Market Capitalization		 502 637 514 736 231 209 233 372 218 124
Book Value per Share		 $3.97 $4.37 $4.58 $5.21 $4.07 $3.18 $3.75 $4.15 $7.42 $1.27
Tangible Book Value per Share		 $3.97 $4.37 $4.58 $5.21 $4.07 $3.18 $3.75 $4.15 $7.42 $1.27
Total Capital		 319 342 347 368 243 184 200 211 221 113
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -328 -344 -355 -370 -247 -189 -203 -213 -226 -117
Capital Expenditures (CapEx)		 0.00 0.02 0.31 0.00 0.02 0.00 0.00 0.01 0.00 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -13 -8.14 -13 -6.46 -7.14 -6.72 -5.14 -4.56 -7.81 -4.53
Debt-free Net Working Capital (DFNWC)		 316 336 342 363 239 182 198 209 219 112
Net Working Capital (NWC)		 316 336 342 363 239 182 198 209 219 112
Net Nonoperating Expense (NNE)		 4.91 4.22 4.01 3.02 7.47 3.56 1.99 1.74 0.00 3.33
Net Nonoperating Obligations (NNO)		 -328 -344 -355 -370 -247 -189 -203 -213 -226 -117
Total Depreciation and Amortization (D&A)		 -1.38 -1.73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.45) ($0.42) ($0.43) ($0.38) ($0.94) ($0.63) ($0.45) ($0.40) $0.00 ($0.87)
Adjusted Weighted Average Basic Shares Outstanding		 56.16M 57.82M 56.49M 52.29M 30.12M 28.04M 28.02M 27.94M 14.62M 13.74M
Adjusted Diluted Earnings per Share		 ($0.45) ($0.42) ($0.43) ($0.38) ($0.94) ($0.63) ($0.45) ($0.40) $0.00 ($0.87)
Adjusted Weighted Average Diluted Shares Outstanding		 56.16M 57.82M 56.49M 52.29M 30.12M 28.04M 28.02M 27.94M 14.62M 13.74M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 56.43M 56.43M 112.85M 54.91M 54.90M 36.30M 28.04M 28.03M 27.99M 16.83M
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -20 -20 -17 -24 -14 -11 -9.45 0.00 -8.67
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Astria Therapeutics' Financials

When does Astria Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Astria Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Astria Therapeutics' net income changed over the last 2 years?

Astria Therapeutics' net income appears to be on an upward trend, with a most recent value of -$94.26 million in 2024, rising from -$51.83 million in 2022. The previous period was -$72.89 million in 2023. View Astria Therapeutics' forecast to see where analysts expect Astria Therapeutics to go next.

What is Astria Therapeutics's operating income?
Astria Therapeutics's total operating income in 2024 was -$111.56 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $111.56 million
How has Astria Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Astria Therapeutics' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Astria Therapeutics have?

Astria Therapeutics' total liabilities were at $23.10 million at the end of 2024, a 100.0% increase from 2023, and a 145.3% increase since 2022.

How much cash does Astria Therapeutics have?

In the past 2 years, Astria Therapeutics' cash and equivalents has ranged from $20.53 million in 2022 to $175.53 million in 2023, and is currently $59.82 million as of their latest financial filing in 2024.

How has Astria Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Astria Therapeutics' book value per share changed from 7.42 in 2022 to 3.97 in 2024, a change of -46.5%.


Related Companies

This page (NASDAQ:ATXS) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...
Crypto 101 Media | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored